Literature DB >> 28302509

Binding mode analyses of NAP derivatives as mu opioid receptor selective ligands through docking studies and molecular dynamics simulation.

Huiqun Wang1, Saheem A Zaidi1, Yan Zhang2.   

Abstract

Mu opioid receptor selective antagonists are highly desirable because of their utility as pharmacological probes for receptor characterization and functional studies. Furthermore, the mu opioid receptors act as an important target in drug abuse and addiction treatment. Previously, we reported NAP as a novel lead compound with high selectivity and affinity towards the mu opioid receptor. Based on NAP, we have synthesized its derivatives and further characterized their binding affinities and selectivity towards the receptor. NMP and NGP were identified as the two most selective MOR ligands among NAP derivatives. In the present study, molecular modeling methods were applied to assess the dual binding modes of NAP derivatives, particularly on NMP and NGP, in three opioid receptors, in order to analyze the effects of structural modifications on the pyridyl ring of NAP on the binding affinity and selectivity. The results indicated that the steric hindrance, electrostatic, and hydrophobic effects caused by the substituents on the pyridyl ring of NAP contributed complimentarily on the binding affinity and selectivity of NAP derivatives to three opioid receptors. Analyses of these contributions provided insights on future design of more potent and selective mu opioid receptor ligands. Published by Elsevier Ltd.

Entities:  

Keywords:  Binding affinity; Dual binding modes; Molecular modeling; NAP derivatives; Opioid receptors; Selectivity

Mesh:

Substances:

Year:  2017        PMID: 28302509      PMCID: PMC5395045          DOI: 10.1016/j.bmc.2017.03.005

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  50 in total

Review 1.  Recent advances in selective opioid receptor agonists and antagonists.

Authors:  Masakatsu Eguchi
Journal:  Med Res Rev       Date:  2004-03       Impact factor: 12.944

2.  Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes.

Authors:  Holger Gohlke; Christina Kiel; David A Case
Journal:  J Mol Biol       Date:  2003-07-18       Impact factor: 5.469

Review 3.  Selective opioid receptor agonists and antagonists: research tools and potential therapeutic agents.

Authors:  D M Zimmerman; J D Leander
Journal:  J Med Chem       Date:  1990-03       Impact factor: 7.446

Review 4.  GPCR agonists and antagonists in the clinic.

Authors:  Joel D A Tyndall; Radhika Sandilya
Journal:  Med Chem       Date:  2005-07       Impact factor: 2.745

Review 5.  Role of kappa-opioid receptors in stress and anxiety-related behavior.

Authors:  Ashlee Van't Veer; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

6.  Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model.

Authors:  P Tejedor-Real; J A Micó; C Smadja; R Maldonado; B P Roques; J Gilbert-Rahola
Journal:  Eur J Pharmacol       Date:  1998-07-31       Impact factor: 4.432

7.  Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles.

Authors:  Robert B Best; Xiao Zhu; Jihyun Shim; Pedro E M Lopes; Jeetain Mittal; Michael Feig; Alexander D Mackerell
Journal:  J Chem Theory Comput       Date:  2012-07-18       Impact factor: 6.006

8.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints.

Authors:  Robert Fredriksson; Malin C Lagerström; Lars-Gustav Lundin; Helgi B Schiöth
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

9.  Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.

Authors:  Guo Li; Lindsey C Aschenbach; Jianyang Chen; Michael P Cassidy; David L Stevens; Bichoy H Gabra; Dana E Selley; William L Dewey; Richard B Westkaemper; Yan Zhang
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

10.  Structural basis for bifunctional peptide recognition at human δ-opioid receptor.

Authors:  Gustavo Fenalti; Nadia A Zatsepin; Cecilia Betti; Patrick Giguere; Gye Won Han; Andrii Ishchenko; Wei Liu; Karel Guillemyn; Haitao Zhang; Daniel James; Dingjie Wang; Uwe Weierstall; John C H Spence; Sébastien Boutet; Marc Messerschmidt; Garth J Williams; Cornelius Gati; Oleksandr M Yefanov; Thomas A White; Dominik Oberthuer; Markus Metz; Chun Hong Yoon; Anton Barty; Henry N Chapman; Shibom Basu; Jesse Coe; Chelsie E Conrad; Raimund Fromme; Petra Fromme; Dirk Tourwé; Peter W Schiller; Bryan L Roth; Steven Ballet; Vsevolod Katritch; Raymond C Stevens; Vadim Cherezov
Journal:  Nat Struct Mol Biol       Date:  2015-02-16       Impact factor: 15.369

View more
  5 in total

1.  Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.

Authors:  Samuel Obeng; Abdulmajeed Jali; Yi Zheng; Huiqun Wang; Kathryn L Schwienteck; Chongguang Chen; David L Stevens; Hamid I Akbarali; William L Dewey; Mathew L Banks; Lee-Yuan Liu-Chen; Dana E Selley; Yan Zhang
Journal:  ACS Chem Neurosci       Date:  2019-02-21       Impact factor: 4.418

2.  Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.

Authors:  Yi Zheng; Samuel Obeng; Huiqun Wang; Abdulmajeed M Jali; Bharath Peddibhotla; Dwight A Williams; Chuanchun Zou; David L Stevens; William L Dewey; Hamid I Akbarali; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2019-01-11       Impact factor: 7.446

3.  Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators.

Authors:  Yi Zheng; Samuel Obeng; Huiqun Wang; David L Stevens; Essie Komla; Dana E Selley; William L Dewey; Hamid I Akbarali; Yan Zhang
Journal:  ACS Chem Neurosci       Date:  2018-07-23       Impact factor: 4.418

4.  Potential Toxicity Risk Assessment and Priority Control Strategy for PAHs Metabolism and Transformation Behaviors in the Environment.

Authors:  Lei Zhao; Mengying Zhou; Yuanyuan Zhao; Jiawen Yang; Qikun Pu; Hao Yang; Yang Wu; Cong Lyu; Yu Li
Journal:  Int J Environ Res Public Health       Date:  2022-09-02       Impact factor: 4.614

5.  Comparison of Pharmacological Properties between the Kappa Opioid Receptor Agonist Nalfurafine and 42B, Its 3-Dehydroxy Analogue: Disconnect between in Vitro Agonist Bias and in Vivo Pharmacological Effects.

Authors:  Danni Cao; Peng Huang; Yi-Ting Chiu; Chongguang Chen; Huiqun Wang; Mengchu Li; Yi Zheng; Frederick J Ehlert; Yan Zhang; Lee-Yuan Liu-Chen
Journal:  ACS Chem Neurosci       Date:  2020-09-24       Impact factor: 4.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.